CoChat

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.

Keedy, Vicki Leigh, Bauer, Todd Michael, Clarke, Jeffrey Melson, Hurwitz, Herbert, Baek, Insun, Ha, Ilho, Ock, Chan-Young, Nam, Su Youn, Kim, Mina, Park, Neunggyu, Kim, Jung Yong, Kim, Seong-Jin · 2018 · Journal of Clinical Oncology
Cited by 33

The DOI matches its Crossref record.

Abstract

3031 Background: Stromal signature regulated by TGF-β pathway is one of the major mechanisms of tumor immune surveillance, leading to resistance to immune checkpoint inhibitors (ICI). Moreover, TGF-β responsive signatures (TBRS) of stromal cells have been associated with poor prognosis. Vactosertib (TEW-7197) is a potent, highly selective, oral inhibitor of TGFBR1. The safety, anti-tumor effect of vactosertib and its association with TBRS levels were evaluated in patients with advanced solid tumors. Based on in-house TCGA analysis, high fibroblast TBRS (F-TBRS) levels were seen in pancreatic, lung, colorectal (CMS4 subtype), and stomach (GS subtype) cancers in association with poor prognosis (adjusted hazard ratio 1.27; P = 1.06 x 10-8). Methods: 29 patients were enrolled in a phase I modified 3+3 dose-escalating study (NCT02160106) and received vactosertib once daily at the dose range of 30~340 mg for 5 days with 2 days off. RNA sequencing of pre-treatment tumor samples in 16 patients were analyzed to evaluate F-TBRS levels defined as geometric mean values of 171 corresponding gene expressions. Results: Vactosertib was safe and well tolerated, and the maximum tolerated dose was not determined. The most common treatment-related AE (TRAE) was fatigue, while G3/4 abdominal pain, AST elevation, and pulmonary edema were each reported in one patient, respectively. One DLT of stroke was seen at 100mg QD. In per-protocol analysis, 6 out of 17 patients who received ≥140 mg achieved stable disease (35.3%) and showed higher F-TBRS levels than those with progressive disease. Conclusions: Vactosertib, a potent and highly selective oral TGFBR1 inhibitor, showed excellent safety with the current dosing schedule. Furthermore, since high F-TBRS levels are well recognized as one of the main mechanisms related to resistance to ICI, vactosertib would be an ideal therapeutic strategy in combination with ICIs or conventional anti-tumor therapies for solid tumors with high F-TBRS levels. Clinical trial information: NCT02160106.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.3031

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 33

Metadata

Authors
Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H., Baek, I., Ha, I., Ock, C.-Y., Nam, S. Y., Kim, M., Park, N., Kim, J. Y., & Kim, S.-J.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
3031-3031
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2891904106
Cited by
33
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.3031
The paper
Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H., Baek, I., Ha, I., Ock, C.-Y., Nam, S. Y., Kim, M., Park, N., Kim, J. Y., & Kim, S.-J. (2018). Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.3031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.